Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Minerva Neurosciences Q2 EPS $(0.43) Beats $(0.90) Estimate

Author: Benzinga Newsdesk | August 14, 2025 03:37pm
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.90) by 52.22 percent. This is a 60.55 percent increase over losses of $(1.09) per share from the same period last year.

Posted In: NERV

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist